SEARCH

SEARCH BY CITATION

Fig S1. Normalization of several receptor subunits for the interleukin (IL)-20 subfamily during the first month of etanercept therapy. In uninvolved (Uninv) and involved (Inv) skin at baseline, as well as involved skin at the indicated weeks of therapy, real-time reverse transcriptase–polymerase chain reaction (RT-PCR) was used to assess the expression of receptor subunits for the IL-20 subfamily of cytokines, including IL-20R1, IL-20R2 and IL-22R1 (all n = 8). Data are derived from clinical responders, presented as percentage expression relative to baseline involved skin (normalized to 100%), and shown as means ± SEM. *P < 0·05, ***P < 0·001, compared with baseline involved skin.

Fig S2. Rapid suppression of keratinocyte activation by 1–2 weeks of etanercept therapy. In uninvolved (Uninv) and involved (Inv) skin at baseline, as well as involved skin at the indicated weeks of therapy, the effect of etanercept on keratinocyte activation/function was assessed by using real-time reverse transcriptase–polymerase chain reaction (RT-PCR) to measure expression of (a–d) the chemokines CXCL1 (n = 11), CXCL8 (n = 16), CCL20 (n = 12) and CXCL10 (n = 11); (e) the proinflammatory cytokine interleukin (IL)-1β (n = 16); (f–h) the antimicrobial peptides human cathelicidin antimicrobial peptide-18/leucine-leucine-37 (hCAP-18/LL-37) (n = 11), human β-defensin (HBD)-2 (n = 10) and HBD-3 (n = 7); and (i–j) the keratinocyte growth factors amphiregulin (AREG, n = 16) and heparin-binding epidermal growth factor-like growth factor (HB-EGF, n = 16). Data are derived from clinical responders, presented as percentage expression relative to baseline involved skin (normalized to 100%), and shown as means ± SEM. *P < 0·05, **P < 0·01, ***P < 0·001, compared with baseline involved skin.

Fig S3. Inflammatory dendritic cells do not decrease significantly during the first month of etanercept therapy. In uninvolved (Uninv) and involved (Inv) skin at baseline, as well as involved skin at the indicated weeks of therapy, area of dermal immunostaining of CD11c (n = 7) was quantified. Data are derived from clinical responders, and are presented as percentage dermal area stained. *P < 0·01.

Fig S4. Lesional T-cell numbers remain stable during the first month of etanercept therapy. In uninvolved (Uninv) and involved (Inv) skin at baseline, as well as involved skin at the indicated weeks of therapy, area of epidermal and dermal immunostaining of CD3, CD4 and CD8 (all n = 7) was quantified. Data are derived from clinical responders, presented as percentage area stained relative to baseline involved skin (normalized to 100%), and shown as means ± SEM. *P < 0·05, **P < 0·01, ***P < 0·001, compared with baseline involved skin.

FilenameFormatSizeDescription
BJD_10961_sm_FigS1.pdf256KSupporting info item
BJD_10961_sm_FigS2.pdf325KSupporting info item
BJD_10961_sm_FigS3.pdf257KSupporting info item
BJD_10961_sm_FigS4.pdf286KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.